Business Wire

The Royal Commission for AlUla Launches Its Second Winter at Tantora Festival of Culture, Heritage and Celebration in Saudi Arabia

Share

The second Winter at Tantora Festival in AlUla in North West Saudi Arabia starts today – a three-month celebration that will showcase the very best in international music, art and culture connecting East and West as the AlUla county has done for thousands of years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005781/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Winter at Tantora: Experience AlUla (Photo : AETOSWire)

It comes just months after Saudi Arabia introduced tourist visas to citizens from 49 countries making the Kingdom more accessible than ever with the UNESCO World Heritage site at Hegra in AlUla among those featured in a global marketing campaign.

The festival is part of the Cultural Manifesto that was launched by the festival organisers, the Royal Commission for AlUla, in Paris in October as part of a long-term strategy to transform the region and open the region as a global living museum and place of culture, heritage and the arts.

Winter at Tantora will cover 12 weekends from 19th December and host a wide range of events from the world-famous Dakar Rally; international ballooning festival; the world’s second longest endurance horse race; the world’s first desert polo tournament and welcome pop-up restaurants from globally renowned restaurants.

The spectacular mirrored wall Maraya Theatre with its 500-seat capacity and operatic sound quality will be home throughout the festival to some of the world’s leading performers who range from Omar Khairat to Andrea Bocelli.

Festival visitors will also be able to meet and engage with young members of the AlUla community who are benefitting from a diverse range of training programmes in hospitality; culture; nature and the environment and studying overseas including 24 men and women at the FERRANDI Paris culinary institute in Paris.

These young chefs will work alongside Michelin-starred experts during the festival creating world-class cuisine that will incorporate local ingredients from the fertile AlUla valley and blending traditional recipes with modern cuisine.

RCU CEO Amr AlMadani says: “Festival visitors will be given a unique opportunity to visit and experience one of the world’s undiscovered places and its spectacular heritage sites before we reopen them to the world in October 2020.

“They will get a tantalising glimpse of a place that been a cultural crossroads for thousands of years and the chance to see it from the serenity of a hot air balloon; the adrenaline of soaring over the desert and mountains in an open seater biplane or exploring hidden canyons in traditional vintage Land Rovers.”

The Royal Commission for AlUla has also completed major infrastructure work at AlUla airport – increasing capacity fourfold to 400,000 visitors a year and upgrading local mountain resorts to enhance the visitor experience.

AlUla will be a worldwide destination for those seeking a unique experience of the full meaning and context of landscape – an experience that integrates the natural and cultural heritage as one living environment. By safeguarding our precious landscapes and cultural heritage this open-air museum will be the Kingdom’s gift to the world creating remarkable and lasting memories.

‘Authentic AlUla’, the opening weekend, is a celebration rooted in AlUla, to mark the start of the winter planting season at the iconic Tantora sundial from which the festival is named. It is the first of 12 specially themed weekends.

Notes to editors

To find out more about the Winter at Tantora festival and details of packages and the entertainment and cultural programmes, log on to www.experiencealula.com

To find out more about how the Royal Commission for AlUla is working with the community to develop a world-class tourism destination, log on to www.rcu.gov.sa

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

RCU Public Relations team
The head of PR at RCU
Antony Newton
PublicRelations@rcu.gov.sa

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye